col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt


36 Ergebisse       Seite 1

 [1] 
Wiley: Pharmacoepidemiology and Drug Safety
  Original Artikel Datum Titel Autoren   Alle Autoren
1 [GO] 2025―Mai―20 Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States Patricia C. Lloyd, Elizabeth R. Smith, Joann F. Gruber, Michelle Ondari, Hui Lee Wong, Mao Hu, et al. (+17)
2 [GO] 2025―Mai―16 Changes in Hormonal Contraceptive Dispensing Trends Among Commercially Insured Kentucky Females During the COVID-19 Pandemic Dustin K. Miracle, Lindsey R. Hammerslag, Svetla Slavova, Feitong Lei, Jeffery Talbert, Daniela C. Moga, Patricia R. Freeman
3 [GO] 2025―Mrz―29 Characteristics and Medication Use Patterns of Pregnancies With COVID-19 Ending in Live-Birth in the Sentinel System Mayura Shinde, Austin Cosgrove, Jennifer G. Lyons, Maria E. Kempner, Jolene Mosley, David Cole, et al. (+10)
4 [GO] 2025―Mrz―11 Regulatory Risk Communication on Thrombosis With Thrombocytopenia Syndrome for COVID-19 Adenovirus Vector Vaccines: Comment Hinpetch Daungsupawong, Viroj Wiwanitkit
5 [GO] 2025―Jan―30 Quantitative Benefit-Risk Assessment of Vaccination Against COVID-19: A Systematic Review E. Claire Newbern, Lea Wildisen, Rita Verstraeten, Corinne Willame, Kevin Haynes, Bennett Levitan, Nicolas Praet
6 [GO] 2025―Jan―23 Lessons Learned From Characterizing Long COVID Among US Medicare Beneficiaries Yun Lu, Arnstein Lindaas, Hector S. Izurieta, Myrna Cozen, Mikhail Menis, Xiangyu Shi, et al. (+5)
7 [GO] 2025―Jan―14 Characterization of SARS-CoV-2 Diagnostic Tests and Liver Function Tests Among Patients With COVID-19 Diagnosed in Outpatient Settings Using Administrative Healthcare Data and Data From Commercial Laboratories Ayad K. Ali, Aidan Baglivo, Priya Govil, Liza R. Gibbs, Marie C. Bradley, Keith E. Campbell, et al. (+4)
8 [GO] 2025―Jan―08 Using Quantitative Bias Analysis to Adjust for Misclassification of COVID-19 Outcomes: An Applied Example of Inhaled Corticosteroids and COVID-19 Outcomes Marleen Bokern, Christopher T. Rentsch, Jennifer K. Quint, Jacob Hunnicutt, Ian Douglas, Anna Schultze
9 [GO] 2024―Nov―26 Impact of Regulatory Risk Communication on Thrombosis With Thrombocytopenia Syndrome for COVID-19 Adenovirus Vector Vaccines on European Healthcare Professionals Ella van Vliet, Nanča Čebron Lipovec, Marloes van der Goot, Shahab Abtahi, Inês Ribeiro -Vaz, Elita Poplavska, et al. (+13)
10 [GO] 2024―Nov―13 Investigating the Safety Profile of Fast-Track COVID-19 Drugs Using the FDA Adverse Event Reporting System Database: A Comparative Observational Study Hyo Jung Kim, Jeong-Hwa Yoon, Kye Hwa Lee
11 [GO] 2024―Okt―25 Validation Study of the Claims-Based Algorithm Using the International Classification of Diseases Codes to Identify Patients With Coronavirus Disease in Japan From 2020 to 2022: The VENUS Study Taku Chikamochi, Chieko Ishiguro, Wataru Mimura, Megumi Maeda, Fumiko Murata, Haruhisa Fukuda
12 [GO] 2024―Okt―18 Dexamethasone Dose for COVID-19 in a Large U.S. Hospital Network From April 2020 to May 2023 Marie C. Bradley, Ashish Rai, Austin Cosgrove, Silvia Perez-Vilar, Candace Fuller, Edward Rosen, et al. (+6)
13 [GO] 2024―Okt―08 Validation Assessment of Privacy-Preserving Synthetic Electronic Health Record Data: Comparison of Original Versus Synthetic Data on Real-World COVID-19 Vaccine Effectiveness Echo Wang, Katrina Mott, Hongtao Zhang, Sivan Gazit, Gabriel Chodick, Mehmet Burcu
14 [GO] 2024―Aug―18 Lack of Evidence for Vaccine-Associated Enhanced Disease From COVID-19 Vaccines Among Adults in the Vaccine Safety Datalink Thomas G. Boyce, David L. McClure, Kayla E. Hanson, Matthew F. Daley, Malini B. DeSilva, Stephanie A. Irving, et al. (+8)
15 [GO] 2024―Aug―13 A Dynamic Prognostic Model for Identifying Vulnerable COVID-19 Patients at High Risk of Rapid Deterioration Priyanka Anand, Elvira D'Andrea, William Feldman, Shirley V. Wang, Jun Liu, Gregory Brill, et al. (+2)
16 [GO] 2024―Aug―05 Nirmatrelvir/Ritonavir (Paxlovid) Use Among Individuals at Risk of Severe COVID-19: An Analysis of the National COVID Cohort Collaborative (N3C) Xuya Xiao, G. Caleb Alexander, Hemalkumar B. Mehta
17 [GO] 2024―Aug―02 Adverse Menstrual Events Reported After and Before (or Without) COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Comparative Observational Studies Frank Peinemann, Doris Oberle, Ursula Drechsel-Bäuerle, Brigitte Keller-Stanislawski
18 [GO] 2024―Apr―03 Validity of inpatient electronic health record-based measures of oxygen-related therapy in the United States: Lessons applicable for studying COVID-19 endpoints Candace C. Fuller, Edward Rosen, Ashish Rai, Austin Cosgrove, Karla Miller, Patricia Bright, et al. (+9)
19 [GO] 2023―Nov―10 The risk of miscarriage after COVID-19 vaccination before and during pregnancy Maud de Feijter, Marleen M. H. J. van Gelder, Lieke C. M. Vissers, Agnes C. Kant, Petra J. Woestenberg
20 [GO] 2023―Sep―16 Altered liver function test after Covid-19 vaccines: A retrospective control group study Fernando Ezequiel Jabif, Marcelo Gabriel Vallone, Vanina Cecilia Stanek, Marlene Padilla Lopez, Natalia Sobenko, Alejandra Maria Villamil, Maria Florencia Grande Ratti
21 [GO] 2022―Nov―10 Understanding the variability of pharmaco-epidemiological studies assessing the risk of appendicitis with mRNA COVID-19 vaccines Clement Jambon-Barbara, Claire Bernardeau, Jean-Luc Cracowski, Charles Khouri
22 [GO] 2022―Nov―05 Social Media for Early Characterization of Pandemic Symptoms: A Qualitative Analysis of Patient-Reported COVID -19 experiences Melissa Khashei, Scott Janiczak, Christopher St. Clair, Wei Liu, Jae Joon Song, Wei Hua, et al. (+2)
23 [GO] 2022―Sep―20 Anti-Osteoporosis Medication dispensing by Clinical Commissioning Groups in England - an ecological study of variability in practice and of the effect of the Covid-19 pandemic S. S. Janjua, H. F. Boardman, A. Sami, A. Johansen, L. S. Toh, M. K. Javaid
24 [GO] 2022―Sep―16 Telemedicine Use Among Patients With Metastatic Breast Cancer During the COVID-19 Pandemic: Differences by Race, Age and Region Gregory S. Calip, Aaron Cohen, Rebecca Rohrer, Xiaoliang Wang, Xiaoyan Wang, Amy We, et al. (+4)
25 [GO] 2022―Aug―23 A Systematic Review of Whether COVID-19 Randomized Controlled Trials Reported on Demographic and Clinical Characteristics Joyce Pak, Jennifer L. Lund, Alexander Keil, Daniel Westreich, Til Stürmer, David Wohl, et al. (+3)
26 [GO] 2022―Aug―10 Thromboembolic events after Ad.26.COV2.S COVID-19 vaccine: reports to the Vaccine Adverse Event Reporting System Emily Jane Woo, Adamma Mba-Jonas, Alisha Thomas, Bethany Baer, Brendan Day, Yeowon Kim, et al. (+2)
27 [GO] 2022―Jul―06 Comparison of Drug Prescribing Before and During the COVID -19 Pandemic - A Cross-national European Study Iva Selke Krulichová, Gisbert W. Selke, Marion Bennie, Mohammadhossein Hajiebrahimi, Fredrik Nyberg, Jurij Fürst, et al. (+14)
28 [GO] 2022―Mai―15 Myopericarditis following COVID-19 mRNA vaccination Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
29 [GO] 2022―Apr―23 International trends in prescription opioid sales among developed and developing economies, and the impact of the COVID -19 pandemic: A cross-sectional analysis of 66 countries Tara Gomes, Katherine Callaway Kim, Katie J. Suda, Ria Garg, Mina Tadrous
30 [GO] 2022―Apr―15 COVID -19 pharmacotherapy utilization patterns during pregnancy: International Registry of Coronavirus Exposure in Pregnancy ( IRCEP ) Whitney J. Westhoff, Louisa H. Smith, Diego F. Wyszynski, Sonia Hernandez-Diaz
31 [GO] 2022―Mrz―17 Pandemic vaccine testing: combining conventional and challenge studies Tobias Gerhard, Brian L. Strom, Nir Eyal
32 [GO] 2021―Dez―09 SARS-CoV -2 vaccine-related adverse events in Zimbabwe: the need to strengthen pharmacovigilance in resource-limited settings Grant Murewanhema, Tafadzwa Dzinamarira, Roda Madziva, Helena Herrera, Godfrey Musuka
33 [GO] 2021―Jul―10 Utilization of drugs with reports on potential efficacy or harm on COVID -19 before, during, and after the first pandemic wave Salka Enners, Gabriele Gradl, Marita Kieble, Michael Böhm, Ulrich Laufs, Martin Schulz
34 [GO] 2021―Mrz―27 QTc prolongation in COVID-19 patients treated with Hydroxychloroquine, Chloroquine, Azithromycin, or Lopinavir/Ritonavir: A systematic review and meta-analysis Carlos Diaz-Arocutipa, Ana Brañez-Condorena, Adrian V. Hernandez
35 [GO] 2021―Mrz―02 Global COVID -19 Pandemic and Reporting Behavior - An Analysis of the Food and Drug Administration Adverse Events Reporting System ( FAERS ) Michael Dörks, Kathrin Jobski, Falk Hoffmann, Antonios Douros
36 [GO] 2020―Mai―05 Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic# Anton Pottegård, Xavier Kurz, Nicholas Moore, Christian F. Christiansen, Olaf Klungel
 [1] 

36 Ergebisse       Seite 1


[de][en]

Letzte Änderung 2023―Okt―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.004 sec